Disclosures. Consultant Thoratec, HeartWare Research Support Thoratec (2012) No off label use/indications will be discussed.

Slides:



Advertisements
Similar presentations
Off pump CABG has been performed for the first time 40 years ago. Although conventional CABG is considered both safe and effective, the use of CBP.
Advertisements

Assisted Circulation MEDICAL MEDICAL  Drugs  EECP MECHANICAL  IABP ( Introaortic balloon pump)  VAD (Ventricular assist device)
AVR: Choice of Prosthesis Tirone E. David University of Toronto.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Use of Psoas Muscle Size as a Frailty Assessment Tool for Open and Transcatheter Aortic Valve Replacement Raghavendra Paknikar BS Jeffrey Friedman BS David.
Long-Term Outcomes and Modes of Failure of the Ross Operation in Patients with Aortic Insufficiency Joel Price MD, MPH, Laurent De Kerchove MD, David Glineur.
Heart Transplantation for Patients with a Fontan Procedure
Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 1 What is the same? What is reduced/removed? What is added/expanded? INTERMACS.
Biventricular Failure – Total Artificial Heart Francisco A. Arabía, MD Director, CHSI Center for Surgical Device Management Cedars-Sinai Heart Institute.
Keith Aaronson, Mark Slaughter, Edwin McGee, William Cotts, Michael Acker, Mariell Jessup, Igor Gregoric, Pranav Loyalka, Valluvan Jeevanandam, Allen Anderson,
Ultra long term outcomes in adult survivors of tetralogy of Fallot and the effect of pulmonary valve replacement Dobson R1,2, Danton M2, Walker N2, Tzemos,
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
Periportal Fibrosis Without Cirrhosis Does Not Affect Outcomes Following Continuous Flow Ventricular Assist Device Implantation Jonathon E. Sargent, BS,
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Presentations: Quantifying the impact of adverse events on HRQOL early after implant Patient selection and estimation of prognosis using health status.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
M Ruel, V Chan, M Boodhwani, B McDonald, X Ni, G Gill, K Lam, F Rubens, P Hendry, R Masters, T Mesana Ottawa, Canada How Detrimental is Re-Exploration.
HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.
MCS in Special Populations: The Use of Mechanical Support in Adults with Congenital Heart Disease 9 th Annual Meeting May 15, 2015 Christina VanderPluym,MD.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
Survival following VAD complications: implications for transplant priority. Todd Dardas, MD, MS May 16, 2015.
Sakakibara Heart Institute Minoru Tabata, MD, MPH, Akihito Matsushita, MD, Toshihiro Fukui, MD, Shigefumi Matsuyama, MD, Tomoki Shimokawa, MD, Shuichiro.
Long-term Benefits of Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus on Right Ventricular Function Brent Keeling MD 1, Bradley G. Leshnower.
Surgical outcome of native valve infective endocarditis in srinagarind hospital
INTERMACS: June 2006 – December 2012: CMS Report Adults: n=7849 All primary implants as of 12/31/2012 n= 7928 Pediatric patients: n=79 (patients < 19 yrs.
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical.
When and How to Replace an LVAD
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children’s.
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
A Contemporary Analysis of Pulmonary Hypertension in Patients Undergoing Mitral Valve Surgery: Is this a Risk Factor? Thank you to the society and panel.
Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.
HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):
“Rise of the Machines” Todd D. Edwards MD FACC FACP FASNC.
MCSRN Mechanical Circulatory Support Research Network
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
The Reoperative Aortic Root: Degenerative Failure vs. Infectious Destruction – Outcomes of The “True Redo-Root” Reconstruction Rita K. Milewski, Arminder.
Concomitant Aortic Valve Repair in Patients Undergoing Continuous-flow Left Ventricular Assist Device Placement: A 10-year Experience and Clinical Implications.
1 Data Quality Report Quality Assurance Report Live Data Download Site Datasets (SAS) Research Datasets Customized Cohort Reports Outcome Analytics Patient.
Michael S Kiernan, MD, SM Assistant Professor, Tufts University Medical Director Ventricular Assist Device Program, Tufts Medical Center.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Primary Mitral Regurgitation Degenerative Mitral Valve Disease
James S. Tweddell, MD Warren W. Bailey Endowed Chair,
Patients Characteristics
Total Artificial Heart (TAH): Survival Outcomes, Risk Factors,
James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L
INTERMACS 10th Annual Meeting March , 2016 Quality of Life
Preoperative screening for LVAD an TAH implantation
Dr M B Connellan Stellenbosch University
Longevity of transcatheter and surgical bioprosthetic aortic valves in patients with severe aortic stenosis and lower surgical risk Lars Sondergaard,
Mechanical circulatory support
Homograft Replacement of the aortic valve:Ten-year results
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
Mechanical Circulatory Support Devices HOSEIN PASANDI.
Long-term mechanical circulatory support (destination therapy): On track to compete with heart transplantation?  James K. Kirklin, MD, David C. Naftel,
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: An 8-year retrospective.
Doubly Committed and Juxtaarterial Ventricular Septal Defect: Outcomes of the Aortic and Pulmonary Valves  Paul J. Devlin, BA, Hyde M. Russell, MD, Michael.
Sarah A. Schubert, MD, Leora T
Adverse events in contemporary continuous-flow left ventricular assist devices: A multi- institutional comparison shows significant differences  John M.
Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011  William L.
William L. Holman, MD, James K. Kirklin, MD, David C
Linking Intermacs to the World:
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Disclosures. Consultant Thoratec, HeartWare Research Support Thoratec (2012) No off label use/indications will be discussed.

Asking a Question? Question (Respondent) What movie would you like to see?( Spouse) Is it cancer?(Radiologist) Would you agree that the standard was not met? (Lawyer) What is the best treatment?(Clinician) What should a surgeon do with AI at the time of a VAD?(INTERMACS) Response Tread lightly- consider previous choices and whose choice was last made. Cannot rule out…. Please restate. It depends. Let’s look at the data.

Aortic Insufficiency Clinician Aspects Mechanical Valve Carries Perceived Risk Of Stroke Aortic Insufficiency Impaisr MCS By Short Circuit Aortic Insufficiency Will Worsen With Time How durable are any of the options? Considerations The addition of ischemic time ( cross clamp) to sick hearts (RV) Cross clamp time varies by technique Don’t Valves and repairs just fuse eventually anyway?

DAAP Suggestions 1) What are the outcomes of patients with important AI who do not undergo an AV procedure compared to those that do have an AV procedure performed; and, Compare important outcomes of patients stratified to the following groups by pre-implant assessment of the degree of AI and subsequent intervention: Group 1: AI – None; Group 2: AI – Mild with NO AV procedure performed; Group 3: AI – Mild with AV procedure performed; Group 4: AI – Moderate or more with NO AV procedure performed; and Group 5: AI – Moderate or more with AV procedure performed. The outcome measures that the DAAP Committee would recommend/suggest to assess would be: 1) survival; 2) duration of inotrope support; 3) freedom from RV failure; 4) renal function (both early and late); 5) duration of ICU stay; 6) total LOS for index hospitalization; 7) freedom from readmission; and 8) freedom from AI – Moderate or more. 2) What are the outcomes of patients that undergo an AV procedure with respect to the type of procedure performed? For those patients that did receive an AV procedure, the patients should be stratified by type of procedure; Group I – AV replacement; Group II – AV repair; Group III – Other AV procedure. The outcome measures that the DAAP Committee would recommend/suggest to follow would be 1: Survival; 2) Freedom from stroke; 3) Freedom from AI – Moderate or More; and 4) Freedom from RV failure. These outcomes measures would importantly assess the stroke risk from each of the procedures and durability of preventing recurrence of AI.

Why INTERMACS? Size of Data Prospective data Data Capture LONGITUDINAL DATA- ALIVE/DEAD/ECHO DATA Nice People.

Adults: n=7808 All Primary Pts implanted As of 12/31/2012 N=7887 Pediatric Patients: n=79 (patients < 19 yrs of age at time of implant) Pulsatile Flow: * N=1087 Continuous Flow: n=6721 Bi VAD: 179LVAD: 6542 BiVAD: 301TAH: 158LVAD: 628 * The left ventricular device indicates the type of pump implanted (continuous flow or pulsatile flow). Patient Pool INTERMACS: June 2006 – December 2012: Aortic Insufficiency 7

A visit to INTERMACS

Problems? Data not complete Apparent Inconsistencies in responses – Severe AI with no procedure???? – Replacement with mechanical valve Previous version did not capture the same fields/data Massive Variation in Clinical practice and terminology.

"The aorta was clamped and infused with cold blood cardioplegia antegrade for a total of 1L. A Transverse aortotomy was made. Mildly to moderately thickened aortic valve lesions were noted. Using three stripes of Teflon and running 4-0 Prolene suture, the aortic valve was closed shut to deal with the aortic insufficiency. The aortomoy was then closed with 4-0 Prolene suture in two layers." "The previously placed Bjork-Shiley valve was visualized. A sandwich felt technique was used to patch the valve from the ventricular and the aortic aspect in order to prevent any exposure of the valave to circulation to reduced the development of thrombosis and passive mobilization. This was done with 2 circular patches sutured together through the aortic valve prosthesis. An additional portion of felt patch had to be used to completely cover the aotic valve on the aortic aspect. The patch was then sewn to the side of the graft to fully exclude the valve. The aortotomy was then closed with 2 running layers of 4-0 Prolene." 3 pledgeted sutures 4 pledgeted matress sutures 4-0 prolene pursestring suture on each leaflet; additional pledgeted 4-0 prolene between rt & lt commissures. A piece of bovine pericardial patch was fashioned to the size of the aortic valve. It was sewn into place to cover the aortic valve using a series of 4 pledgeted 4-0 Prolene sutures. All had notes that stated AV was repaired, but in details in the notes all were found to have been oversewn with leaflets closed. Aortic VALVE OVERSEWN-pericardial patch AV oversewn closed w/ pledgetted suture and prolene N/A Oversewing of aortic valve Pre-exisiting MECHANICAL AV SURGERY--Aortic VALVE OVERSEWN-percardial patch Replacement of aortic valve with Hemashield patch These were the good ones!

INTERMACS: June 2006 – December 2012: Aortic Insufficiency Additional Data Collection Summary Question 1: Patients with Moderate/Severe Aortic Insufficiency at time of implant but no concomitant AV surgery recorded: patients=131, hospitals=59 Question 2: Patients with Documented Concomitant Aortic Repair at time of implant – verification of AV closure and/or AV repair: patients=213, hospitals=62 Total Patients = 326 Total Hospitals = 88 11

INTERMACS: June 2006 – December 2012: Aortic Insufficiency Groups nLVADBiVAD 1)Aortic Closure )Aortic Repair )Aortic Replacement – Bio/Mech )All Others Total Group distribution AFTER finalization of additional data collection 13 Final Groups nLVADBiVAD 1)Aortic Closure )Aortic Repair )Aortic Replacement – Bio/Mech )All Others Total Original Groups prior to additional data collection

INTERMACS: June 2006 – December 2012: Aortic Insufficiency Aortic Regurg – Pre-implant Groups nNoneMildModSev Unknown 1)Aortic Closure (14.0%) 58 (42.6%)34 (25.0%) 8 (5.9%) 17 (12.5%) 2)Aortic Repair (12.1%) 69 (41.8%)47 (28.5%) 1 (0.7%) 28 (16.9%) 3)Aortic Replacement (Bio/Mech) (11.7%) 33 (32.0%)28 (27.2%) 7 (6.8%) 23 (22.3%) 4)All Others (56.7%)1348 (21.3%)83 (1.3%)14 (0.2%) 1288 (20.4%) Total (54.1%)1508 (22.4%)192 (2.9%)30 (0.4%) 1356 (20.2%) Group Summary AFTER finalization of additional data collection 14 Aortic Regurg – Pre-implant Groups nNoneMildModSev 1)Aortic Closure (16.0%) 58 (48.7%)34 (28.6%) 8 (6.7%) 2)Aortic Repair (14.6%) 69 (50.4%)47 (34.3%) 1 (0.7%) 3)Aortic Replacement (Bio/Mech) (15.0%) 33 (41.3%)28 (35.0%) 7 (8.7%) 4)All Others (71.3%)1348 (26.8%)83 (1.6%)14 (0.3%) Total (67.8%)1508 (28.1%)192 (3.5%)30 (0.6%)

INTERMACS: June 2006 – December 2012: Aortic Insufficiency COD Summary AFTER finalization of additional data collection 15 Group 1 = Aortic Closure Primary Cause of Deathn % Circulatory: Arterial Non-CNS Thromboembolism Circulatory: Myocardial Infarction Circulatory: Other, Specify Device Malfunction Major Infection Respiratory: Respiratory Failure Respiratory: Pulmonary: Other, specify Circulatory: Sudden Unexplained Death Other: Trauma/accident, specify Circulatory: Major Bleeding Digestive: Hepatic Dysfunction Nervous System: Neurological Dysfunction Multisystem Organ Failure Withdrawal of Support, specify Circulatory: Cardiac Arrhythmia Other/Unknown Totals Group 2 = Aortic Repair Primary Cause of Deathn % Other: Cancer Circulatory: Myocardial Infarction Circulatory: Other, Specify Major Infection Respiratory: Pulmonary: Other, specify Digestive: Renal Dysfunction Circulatory: Sudden Unexplained Death Other: Trauma/accident, specify Circulatory: Right Heart Failure Circulatory: Major Bleeding Circulatory: CHF Circulatory: End Stage Cardiomyopathy Digestive: Hepatic Dysfunction Nervous System: Neurological Dysfunction Multisystem Organ Failure Circulatory: Cardiac Arrhythmia Other/Unknown Total

16

Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis Jason Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil Prasad, M.D.; Akinobu Itoh, M.D.; Susan Myers; Gail Mertz, B.S., R.N., CCRC; James Kirklin, M.D.; and Scott Silvestry, M.D. April 11, 2014 Disclosures: Robertson – none; Naftel – none; Prasad - none; Itoh – none; Myers – none; Mertz – none; Kirklin – none; Silvestry – Consultant for Thoratec and HeartWare This project has been funded in whole or in part with federal funds from the National Heart, Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN C

Outcomes Following Aortic Valve Procedures Previous studies have disagreed on whether mortality after concomitant aortic valve procedures is increased, with some studies demonstrating equivalent or improved survival. The largest of these used data from the HeartMate II BTT and DT Trials (n=1,106), including: 30 AVRs 32 AV closures 18 AV repairs Long term survival was significantly reduced compared to HMII implant alone: 1-year Survival: 57% vs. 75%, p= year Survival: 43% vs. 64%, p=0.001 Dranishnikov N, et al. Int J Artif Organs. 2012; 35 (7): John R, et al. JTCVS. 2014; 147: Pal JD, et al. Circulation. 2009; 120: S Adamson RM, et al. JHLT. 2011; 30: Goda A, et al. Ann Thorac Surg. 2011; 91: Morgan JA, et al. JHLT. 2013; 32:

INTERMACS Database Additional Data Collection Summary Question 1: Audit of patients with documented moderate/severe AI without a documented AVP to determine if an AVP was in fact performed: Queried: patients=113 hospitals=59 Responded: patients=86 (76%) hospitals=47 (80%) Question 2: Clarification of whether patients with documented AV repairs underwent a closure or a repair: Queried: patients=213 hospitals=62 Responded:patients=143(67%) hospitals=40 (65%) Unconfirmed:patients=70 (33%)hospitals=19 (31%) Total Patients queried = 326 Total Hospitals queried = 88 Total Patients with response = 229 (70%) Total Hospitals responded = 63 (72%)

Adults: N=7,808 All patients implanted as of 12/31/2012 N=7,887 All patients implanted as of 12/31/2012 N=7,887 Pediatric Patients: N=79 (patients < 19 yrs of age at time of implant) Pediatric Patients: N=79 (patients < 19 yrs of age at time of implant) Pulsatile Flow: N=1,087 N=1,087 Continuous Flow: N=6,721 Bi VAD: N=179 LVAD: N=6,542 BiVAD N=301 TAHN=158TAHN=158LVADN=628LVADN=628 INTERMACS Patient Population: June 2006 – December 2012 Bi VAD: N=140 LVAD: N=5,204 Total Cohort: N=5,344 Database Audit Reduced Cohort: Mean Follow-up = 12.3 months

Aortic Valve Closure Total=125Total=125 LVAD=121LVAD=121 BiVAD=4BiVAD=4 Aortic Valve Repair Total=95Total=95 LVAD=93LVAD=93 BiVAD=2BiVAD=2 Aortic Valve Replacement Total=85Total=85 LVAD=83LVAD=83 BiVAD=2BiVAD=2 All Others Total=5,039Total=5,039 LVAD=4,907LVAD=4,907 BiVAD=132BiVAD=132 INTERMACS Patient Population: June 2006 – December 2012

Event = Death with a device in place (censored at transplant or recovery) Months Post Implant % Survival AV Repair n=95, deaths=22 AV Closure, n=125, deaths=46 AV Replacement n=85, deaths=24 Overall p = No AV Procedure n=5039, deaths=1078 Survival by Type of Aortic Valve Procedure Performed

Months Post Implant % Survival % Survival post implant Groups n events 6 months 1 year AV Closure % 56% AV Repair % 76% AV Replacement % 67% No AVP % 79% Survival for INTERMACS Level 1-2 Patients by Type of AVP Overall p=0.003

Months Post Implant % Survival Overall p = 0.04 % Survival post implant Groups n events 6 months 1 year AV Closure % 73% AV Repair % 82% AV Replacement % 75% No AVP % 84% Survival for INTERMACS Level 3-7 Patients by Type of AVP

Multivariate Model for Death After Implant Risk FactorHazard RatioConfidence Interval P-value Aortic Regurgitation AV Repair AVR Closure < INTERMACS Level Dialysis BiVAD < Risk FactorHazard RatioConfidence Interval P-value Aortic Regurgitation AV Repair AVR Closure < INTERMACS Level Dialysis BiVAD < Risk FactorHazard RatioConfidence Interval P-value Aortic Regurgitation AV Repair AVR Closure < INTERMACS Level Preop Dialysis BiVAD <0.0001

Aortic Closure, n=112 Aortic Repair, n=85 Aortic Replacement, n=67 No AV Procedure, n=4,061 % of Patients with Moderate/Severe Aortic Regurgitation Note: If the total n for the group is < 20 then it is not plotted in this figure. p (6 months) < Recurrence of Aortic Insufficiency Postoperatively by Group

27

Question Answered? Elements of Spouse, Radiologist, Lawyer, clinician answers rolled up into one. Our study highlights some of the strengths and weakness of the data in INTERMACS Clinical Question answered but questions remain. –Role of CPB/Cross Clamp –Clinician Bias? –Non Responsive centers- some want in. 28

Thank You to INTERMACS 29